BiomX Inc. — Director's Dealing 2021

Jul 31, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BiomX Inc. (PHGE)
CIK: 0001739174
Period of Report: 2021-07-28

Reporting Person: OrbiMed Israel BioFund GP Limited Partnership (10% Owner)
Reporting Person: OrbiMed Israel GP Ltd. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-28	Common Stock, $0.0001 par value	P	500000	—	Acquired	2813489	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-28	Warrants (Right to Buy)	$5.00	P	375000	Acquired	2027-01-28	Common Stock (375000)	Indirect

Footnotes

F1: In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.

F2: The purchase reported on this Form 4 were made by OIP. Following the transactions reported on this Form 4, OIP LP is the direct owner of 2,172,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of OIP and OII. By virtue of these relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and OII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Nissim Darvish, Anat Naschitz, and Erez Chimovits.

F3: This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.